Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Medtronic
Mallinckrodt
Merck

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ASP2215

See Plans and Pricing

« Back to Dashboard

Drug Development Status for ASP2215: Sponsors, patents, clinical trial progress

ASP2215 is an investigational drug.

There have been 16 clinical trials for ASP2215. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Astellas Pharma Global Development, Inc., Astellas Pharma Inc, and Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG).

There are two US patents protecting this investigational drug and thirty-eight international patents.

Recent Clinical Trials for ASP2215
TitleSponsorPhase
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 MAstellas Pharma Global Development, Inc.Phase 3
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 MDeutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)Phase 3
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 MStichting Hemato-Oncologie voor Volwassenen NederlandPhase 3

See all ASP2215 clinical trials

Clinical Trial Summary for ASP2215

Top disease conditions for ASP2215
Top clinical trial sponsors for ASP2215

See all ASP2215 clinical trials

US Patents for ASP2215

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP2215   Start Trial Diamino heterocyclic carboxamide compound Astellas Pharma Inc. (Tokyo, JP) Kotobuki Pharmaceutical Co., Ltd. (Hanishina-gun, JP)   Start Trial
ASP2215   Start Trial Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (Tokyo, JP) KOTOBUKI PHARMACEUTICAL CO., LTD. (Nagano, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Johnson and Johnson
Moodys
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.